Baseline patient and lesion characteristics of randomised trials
| ABSORB II, 2015 | ABSORB III, 2015 | ABSORB CHINA, 2015 | ABSORB JAPAN, 2015 | EVERBIO II, 2015 | ABSORB STEMI TROFI II ST, 2016 | |
|---|---|---|---|---|---|---|
| Patients (n) | 501 | 2008 | 480 | 400 | 238 | 191 |
| BVS (n) | 335 | 1322 | 241 | 266 | 78 | 95 |
| DES (n) | 166 | 686 | 239 | 134 | 160 | 96 |
| Male (%) | 77 | 70 | 72 | 77 | 79 | 82 |
| Mean age (year) | 61 | 63 | 57 | 67 | 65 | 59 |
| Diabetes (%) | 24 | 31 | 24 | 36 | 23 | 16 |
| Follow-up (months) | 24 | 12 | 12 | 12 | 9 | 6 |
| GPI use (%) | ||||||
| BVS | NR | 10.1 | NR | NR | NR | 40 |
| DES | NR | 12.4 | NR | NR | NR | 38.5 |
| DAPT duration (months) | Up to 24 | 12 | 12 | 12 | 6 | 12 |
| Device type | BVS, EES | BVS, EES | BVS, EES | BVS, EES | BVS, EES, BES | BVS, EES |
| Intracoronary imaging used (OCT/IVUS %) | ||||||
| BVS | 100 | 11.2 | 0.4 | 100 | NR | 0 |
| DES | 100 | 10.8 | 0.4 | 100 | NR | 0 |
| ACC/AHA lesion class (%) | ||||||
| A | 1.1 | NR | 9.5 | 3.8 | 24.9 | NR |
| B1 | 52.1 | NR | 21.7 | 20.1 | 44 | NR |
| B2 | 45.3 | 69.9* | 49 | 53.8 | 15 | NR |
| C | 1.4 | 24.5 | 22 | 16 | NR | |
| Device predilation (%) | ||||||
| BVS | 100 | 100 | 99.6 | 100 | NR | 55.8 |
| DES | 99 | 100 | 98 | 100 | NR | 51 |
| Device postdilation (%) | ||||||
| BVS | 61 | 65.5 | 63 | 82.2 | 34 | 50.5 |
| DES | 59 | 51.2 | 54.4 | 77.4 | 31 | 25.5 |
| Expected maximum diameter of postdilation balloon (mm) | ||||||
| BVS | 3.29 | 3.18 | 3.3 | 3.34 | NR | 3.51 |
| DES | 3.35 | 3.12 | 3.2 | 3.31 | NR | 3.29 |
| Final dilation pressure (atm) | ||||||
| BVS | 14.2 | 15.4 | 16.8 | 14.7 | 13.6 | 15.8 |
| DES | 15 | 15.4 | 16.9 | 15.1 | 14.2 | 18.6 |
| Clinical presentation (%) | ||||||
| STEMI | 0 | 0 | 0 | 0 | 9.6 | 100 |
| Non-STEMI | 0 | 0 | 0 | 0 | 21 | 0 |
| Unstable angina | 20.9 | 26 | 64.4 | 12 | 8.4 | 0 |
| Stable angina | 63.8 | 58.4 | 19.5 | 64.5 | 48.3 | 0 |
| Silent ischaemia | 12.1 | 10 | 4.6 | 23.5 | 12.6 | 0 |
Values are means or (%).
*B2+C lesions.
BES, biolimus-eluting stent; BVS, bioresorbable vascular scaffold; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; EES, everolimus eluting stent; GPI, glycoprotein IIb/IIIa inhibitors; IVUS, intravascular ultrasound; NR, not reported; OCT, optical coherence tomography; STEMI, ST-elevation myocardial infarction.